Professor Paul Ellis is Professor of Cancer Medicine based at King’s College London and Consultant Medical Oncologist at Guy’s & St Thomas’ Hospital.
Prof Ellis has responsibility for the management of breast cancer.
He studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital in London. He took up his present post in 1997 and has held a number of senior management roles since then including Head of Medical Oncology at Guy’s & St Thomas’, Medical Director for the South East London Cancer Network (SELCN) and Head of Breast Cancer Clinical Research for Guy’s & St Thomas’ and the KCL Division of Cancer Medicine.
He is the author of over 100 peer reviewed scientific papers in the breast cancer field, and has been on the Editorial Board of a number of Oncology Journals including Journal of Clinical Oncology. His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of novel therapies. He was involved in chairing the UK Dept of Health Advisory committee on the introduction of Herceptin into UK clinical practice, and co-authouring the national guidelines on Herceptin use.
Professor Ellis was the principal investigator and co-chair of the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including being Co-PI on the MARIANNE and KAMILLA trials. He continues to take an active leadership role within the UK and European Clinical Trials community.
Over the last 5 years he has been actively involved in the development and growth of the Sarah Cannon Research Centre in London. He has taken a leadership role in the breast programme and links closely with Sarah Cannon in Nashville and the other centres in the US.